GMED Globus Medical Inc Class A

Globus Medical Trauma Division Awarded Purchasing Agreement with Premier Inc.

Globus Medical Trauma Division Awarded Purchasing Agreement with Premier Inc.

AUDUBON, Pa., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, was recently awarded a group purchasing agreement with Premier, one of the largest group purchasing organizations in the United States. The agreement covers Globus’ Trauma Platform, which includes ANTHEM® Plating, AUTOBAHN® Nailing, ARBOR® External Fixation, and CAPTIVATE® Screw Platforms.

"We are very pleased that Premier has selected Globus Medical as a contracted supplier for our Trauma Platform,” said Dan Scavilla, Executive Vice President, Chief Commercial Officer & President, Trauma. “Our mission is to become the pre-eminent musculoskeletal company in the world by expanding our presence in spine, imaging navigation and robotics, trauma, and joint reconstruction in support of strong healthcare providers like Premier’s members.”

To learn more about the complete line of Globus Medical Trauma products, visit

About Globus Medical, Inc.

, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at .

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns

Senior Vice President, Business Development and Investor Relations

Phone: (610) 930-1800

Email:  

 



EN
09/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

Globus Medical Inc: 1 director

A director at Globus Medical Inc sold 10,590 shares at 51.990USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

Globus Medical Reports Fourth Quarter and Full Year 2023 Results AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basisGAAP net income for the quarter was $15.0 millionGAAP diluted earnings per share (“EPS”) was $0.11 and non-GAAP diluted EPS was $0.60Non-GAAP adjusted EBITDA was $17...

 PRESS RELEASE

Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Re...

Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call AUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...

 PRESS RELEASE

Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chi...

Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer Pfeil takes on expanded responsibilities while Globus fuels its next phase of growth AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO). Having served as the Company’s CFO since August 2019, in this expanded role, Pfeil will help further drive the Company's strategic roadmap through business and operational pla...

 PRESS RELEASE

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023. The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis. Full year 2023 sales are expected to be approximately $1.567 billion, an increase of 53.2 percent ove...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch